Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?

Anti-EGFR therapy and antiangiogenic therapies are used alone or in combination with chemotherapies to improve survival in metastatic colorectal cancer. However, it is unknown whether pretreatment with antiangiogenic therapy could impact on the efficacy of anti-EGFR therapy. We selected one hundred...

Descripción completa

Detalles Bibliográficos
Autores principales: Derangère, Valentin, Fumet, Jean David, Boidot, Romain, Bengrine, Leila, Limagne, Emeric, Chevriaux, Angélique, Vincent, Julie, Ladoire, Sylvain, Apetoh, Lionel, Rébé, Cédric, Ghiringhelli, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891042/
https://www.ncbi.nlm.nih.gov/pubmed/26824184
http://dx.doi.org/10.18632/oncotarget.7008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891042/
https://www.ncbi.nlm.nih.gov/pubmed/26824184
http://dx.doi.org/10.18632/oncotarget.7008

Ejemplares similares